The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Now, Eli Lilly is hoping to spark a similar change ... the same year to look for portrayals of obesity, cancer, dementia, diabetes and eczema. The results proved underwhelming, leading the study ...